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Abstract
Cathepsin L is a lysosomal cysteine proteinase primarily
devoted to the metabolic turnover of intracellular proteins.
However, accumulating evidence suggests that this endopep-
tidase might also be implicated in the regulation of other
important biological functions, including bone resorption in
normal and pathological conditions. These findings support
the concept that cathepsin L, in concert with other proteolytic
enzymes involved in bone remodeling processes, could con-
tribute to facilitate bone metastasis formation. In support of
this hypothesis, recent studies indicate that cathepsin L can
foster this process by triggering multiple mechanisms which,
in part, differ from those of the major cysteine proteinase of
osteoclasts, namely cathepsin K. Therefore, cathepsin L can
be regarded as an additional target in the treatment of patients
with metastatic bone disease. This review discusses the clin-
ical and therapeutic implications related to these findings.
Keywords: bone metastasis; cancer; cathepsin K; cathepsin
L; cysteine proteinases; proteinase inhibitors.
Introduction
Bone metastasis is a frequent complication of certain solid
tumors (Mundy, 2002). Patients with metastatic bone disease
are at high risk of skeletal related events (SREs) such as
pathological fracture, nerve compression syndrome, debili-
tating bone pain and hypercalcemia (Mundy, 2002). Current
clinical treatments of this pathological condition are merely
palliative and do not provide a life-prolonging benefit to met-
astatic patients (Mundy, 2002; Lipton, 2007). Consequently,
in recent years, consistent efforts have been directed to the
discovery of new molecules which could be effective to
inhibit SREs and to prevent bone metastasis formation (Mun-
dy, 2002; Lipton, 2007). These studies have identified, as
possible molecular targets, several proteolytic enzymes
including some cysteine proteinases, which appear to be
implicated in the regulation of normal and pathological bone
turnover (Maciewicz et al., 1990; Brage et al., 2005; Everts
et al., 2006; Solau-Gervais et al., 2007; Charni-Ben Tabassi
et al., 2008; Wilson and Singh, 2008). Among cysteine pro-
teinases, cathepsin K, an endopeptidase predominantly
expressed in osteoclasts, is currently thought to play a major
role in pathological conditions associated with an altered
bone resorption including cancer induced osteolysis (Kivi-
ranta et al., 2005; Le Gall et al., 2008; Wilson and Singh,
2008). Therefore, many studies in the field of lysosomal cys-
teine proteinases and bone metastases, undertaken in the past
decade, have focused their attention mainly on this enzyme,
perhaps underscoring the potential involvement of other pro-
teinases of this family and, in particular, that of cathepsin L,
a lysosomal endopeptidase which participates in tissue deg-
radation and extracellular matrix remodeling and which
makes a significant contribution to the degradation of bone
matrix (Maciewicz et al., 1990; Hill et al., 1994; Li et al.,
2004; Brage et al., 2005; Kiviranta et al., 2005; Everts et al.,
2006; Charni-Ben Tabassi et al., 2008; Lion et al., 2009;
Ogawa et al., 2009). By contrast, the hypothesis that cathep-
sin L can contribute to bone metastasis formation is sup-
ported by many experimental and clinical observations,
which highlight that the expression levels of this proteinase
are deregulated in bone diseases with an elevated bone turn-
over (Hill et al., 1994; Park et al., 1996; So¨derstro¨m et al.,
2001; Lang et al., 2004; Lindeman et al., 2004; Schedel et
al., 2004; Kido et al., 2007; Solau-Gervais et al., 2007; Hus-
mann et al., 2008; Wilson and Singh, 2008) and that the
administration of selective cathepsin L antagonists can inhib-
it and prevent cancer induced bone resorption in mice (Hill
et al., 1994; Katunuma et al., 2002a,b; Long and Chagno-
vich, 2009) (Figure 1●●Figure 1 was not cited in the original
paper. Please cite accordingly●●).
Cathepsin L structure and function
Cathepsin L (EC 3.4.22.15) is a lysosomal cysteine endo-
peptidase synthesized as a 39-kDa inactive precursor form
which is normally activated in the acidic environment of
lysosomes (Chauhan et al., 1993; Rawlings et al., 2010). The
active form of this enzyme consists of a heavy chain of
approximately 21 kDa and a light chain of approximately
5 kDa (Chauhan et al., 1993; Rawlings et al., 2010). In
humans, the gene encoding for cathepsin L (CTSL) maps to
chromosome 9q21–q22 and contains eight exons and seven
introns (Chauhan et al., 1993; Rawlings et al., 2010). This
locus is adjacent to another gene coding for a cathepsin L-
like protein, namely cathepsin L2 (also known as cathepsin
V) which share a 80% protein sequence identity with cathep-
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Figure 1 Schematic representation of the possible, multiple mechanisms by which cathepsin L could facilitate bone metastasis formation.
(A) Cathepsin L secreted by cancer cells can directly degrade bone extracellular matrix thus promoting tumor cells invasion and metastasis.
(B) Additionally, the enzyme can indirectly promote this process by triggering the activation latent precursor forms of other enzymes
involved in the metastatic cascade such as matrix metalloproteinases (MMPs) and urokinase type plasminogen activator (uPA). (C) Following
the upregulation of cathepsin L by proinflammatory cytokines which promote bone pit formation, the enzyme can contribute to degrade
bone matrix by the mechanisms described above. (D) Similar to other proteinases such as cathepsin B and MMPs, cathepsin L can degrade
E-cadherin, an adhesion molecule which is downregulated in metastatic tumor cells, thus enhancing their migratory and invasive ability.
(E) Finally, cathepsin L might also facilitate bone metastasis formation by promoting tumor angiogenesis by multiple mechanisms: (i)
activation of latent forms of proteolytic enzymes promoting tumor neovascularization such as uPA and MMPs and (ii) upregulation VEGF
in tumor cells. See text for details and related references.
sin L and a 75% amino acid sequence identity with mouse
cathepsin L (Bro¨mme et al., 1999). However, despite their
high amino acid sequence homology, these enzymes differ
in their tissue distribution and biological functions. In fact,
whereas cathepsin L is expressed in most eukaryotic cells,
cathepsin V expression is restricted to a limited number of
tissues and cells, namely corneal epithelium, epidermis, tes-
tes, thymus and activated macrophages (Chauhan et al.,
1993; Bro¨mme et al., 1999; Bernard et al., 2003; Yasuda et
al., 2004). Furthermore, cathepsin L is mainly involved in
the metabolic turnover of intracellular and secreted regula-
tory proteins (Chauhan et al., 1993; Collette et al., 2004;
Rawlings et al., 2010), whereas the biological effects of
cathepsin V appear to be confined to some specific immu-
nological functions and to the regulation of epidermis home-
ostasis (Hagemann et al., 2004; Yasuda et al., 2004). The
intracellular activity of these proteinases is regulated by
endogenous inhibitors of the cystastins superfamily (Turk et
al., 2008). However, the biological functions of cathepsin L
are not merely confined to the breakdown of intracellular
proteins but also comprise other important processes such as
apoptosis and tissue homeostasis (Hagemann et al., 2004;
Potts et al., 2004; Stoka et al., 2007; Luft, 2009; Dennema¨r-
ker et al., 2010; Lankelma et al., 2010), immune response
(Hsing and Rudensky, 2005; Zavasnik-Bergant and Turk,
2007), activation of latent forms of other proteolytic enzymes
(Everts et al., 2006; Laurent-Matha et al., 2006; Abboud-
Jarrous et al., 2008) and hormone production and processing
(Yasothornsrikul et al., 2003; Funkelstein et al., 2008). The
active role of cathepsin L in some of these processes is fur-
ther confirmed by in vivo studies which show that cathepsin
L-deficient mice exhibit distinct defects in MHC class II
processing in thymic cortical epithelial cells, impaired myo-
cardial functions, epithelial hyperplasia, hypotrichosis and
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Table 1 Cathepsin L in bone.
Study References
Present in rodent osteoclasts Maciewicz et al., 1990; Rifkin et al., 1991;
Ohsawa et al., 1993; Tagami et al., 1994;
Kakegawa et al., 1995;
Furuyama and Fujisawa, 2000a;
Goto et al., 2003; Czupalla et al., 2006
Present in human osteoclasts Nakase et al., 2000; Ishibashi et al., 2001;
Li et al., 2004; Everts et al., 2006;
Perez-Amodio, 2006 ((●●This reference is not listed in ref list pls confirm●●));
Charni-Ben Tabassi et al., 2008
Colocalization with the collagen Goto et al., 2003
fibrils and bone matrix under the
ruffle border of rat osteoclasts
Upregulation of osteoclast Tagami et al., 1994; Kakegawa et al., 1995;
cathepsin L activity and secretion Katunuma et al., 2002a,b●●a or b?●●;
by cytokines promoting bone Furuyama and Fujisawa, 2000a,b;
resorption (PTH), c-Src-TK, Pang et al., 2005; Hashimoto et al., 2006
IL-1a, IL-6, TNF-a
Degradation of bone matrix Maciewicz et al., 1990; Kakegawa et al., 1995;
proteins Everts et al., 2006; Charni-Ben Tabassi et al., 2008;
Lion et al., 2009; Ogawa et al., 2009
Altered bone structure in Potts et al., 2004; Kiviranta et al., 2005;
cathepsin L knockout mice Everts et al., 2006
Altered expression levels in Keyszer et al., 1998; Lang et al., 2004;
non-malignant pathological Potts et al., 2004; Schedel et al., 2004;
conditions associated with an Kido et al., 2007; Solau-Gervais et al., 2007
enhanced bone turnover
progressive hair loss (Reinheckel et al., 2001; Hagemann et
al., 2004; Potts et al., 2004; Luft, 2009) and reduced pro-
duction and secretion of neurotransmitters and hormones
(Yasothornsrikul et al., 2003; Funkelstein et al., 2008).
Cathepsin L in bone remodeling
In addition to the biological functions described above,
experimental evidence suggests that cathepsin L can also be
implicated in the regulation of bone resorption in normal and
pathological conditions (Table 1). This hypothesis is sup-
ported by many biochemical and immunohistochemical stud-
ies which show that this proteinase is present in rodent
osteoclasts (Maciewicz et al., 1990; Rifkin et al., 1991;
Ohsawa et al., 1993; Tagami et al., 1994; Kakegawa et al.,
1995; Furuyama and Fujisawa, 2000a; Goto et al., 2003;
Czupalla et al., 2006) and in human osteoclasts (Nakase et
al., 2000; Ishibashi et al., 2001; Li et al., 2004; Everts et al.,
2006; Perez-Amodio et al., 2006; Charni-Ben Tabassi et al.,
2008) where it could contribute to degrade several compo-
nents of bone extracellular matrix (Maciewicz et al., 1990;
Li et al., 2004; Everts et al., 2006; Charni-Ben Tabassi et al.,
2008; Lion et al., 2009; Ogawa et al., 2009) (Table 1). Fur-
thermore, immunoelectron microscopy studies reveal that, in
rat osteoclasts, cathepsin L is closely associated with the col-
lagen fibrils and bone matrix under the ruffle border of these
cells (Goto et al., 2003). Although the expression levels of
this proteinase in osteoclasts result in highly variable and are
much more lower than that of cathepsin K (Rifkin et al.,
1991; Drake et al., 1996; Everts et al., 2006; Perez-Amodio
et al., 2006), it has been shown that, in vitro, the intracellular
activity and secretion of cathepsin L in these cells could be
upregulated following the release, in the microenvironment,
of cytokines which modulate bone resorption such as para-
thyroid hormone (PTH) (Tagami et al., 1994; Kakegawa et
al., 1995; Furuyama and Fujisawa, 2000b), c-Src tyrosine
kinase (c-Src-TK) (Furuyama and Fujisawa, 2000a), inter-
leukin-1a (IL-1a) (Furuyama and Fujisawa, 2000b), inter-
leukin-6 (IL-6) (Damiens et al., 2000; Furuyama and
Fujisawa, 2000b), tumor necrosis factor-a (TNF-a) (Kake-
gawa et al., 1995; Furuyama and Fujisawa, 2000b; Katunu-
ma et al., 2002a; Hashimoto et al., 2006) and interferon-g
(Pang et al., 2005). In particular, some of these studies show
that PTH and TNF-a can increase the secretion of a precur-
sor form of cathepsin L into culture medium from a bone
cell mixture (Tagami et al., 1994; Kakegawa et al., 1995;
Furuyama and Fujisawa, 2000a,b; Katunuma et al., 2002a).
The pro-enzyme can then be rapidly converted, under acid
conditions, in the mature form and can promote bone pit
formation (Kakegawa et al., 1995; Furuyama and Fujisawa,
2000b). Interestingly, these effects are inhibited by E-64, a
non-selective cysteine proteinase inhibitor but not by CA-
074, a specific inhibitor of cathepsin B (Furuyama and Fuji-
sawa, 2000b; Montaser et al., 2002). By contrast, the
possible involvement of cathepsin L in bone resorption is
further supported by in vivo studies which show that cathep-
sin L knockout mice (B6;129-Ctsltm1Alpk) present alterations
in bone structure (Potts et al., 2004). However, these alter-
ations are different from the osteopetrotic phenotype type
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observed in cathepsin K-deficient mice (Potts et al., 2004;
Kiviranta et al., 2005). In particular, the histomorphometric
examination of the bone in the cathepsin L heterozygote and
homozygote mice shows a significant reduction of trabecular
bone volume, but not that of cortical volume, compared with
wild type mice (Potts et al., 2004). This effect was associated
with a concomitant reduction in the number of osteoclasts
eroding the mineralized cartilagine ●●Should this be carti-
lage?●● (Potts et al., 2004). These findings could fit well
with previous observations from other studies which suggest
a specific role for cathepsin L in the process of endochon-
drial ossification (Nakase et al., 2000; Uusitalo et al., 2000)
and further support the hypothesis of a complementary role
of this protease in bone resorption (Kakegawa et al., 1995;
Furuyama and Fujisawa, 2000a,b; Potts et al., 2004; Kivi-
ranta et al., 2005; Everts et al., 2006; Schurigt et al., 2008;
Long and Chagnovich, 2009).
Cathepsin L in metastatic bone disease
Accumulating evidence suggests that cathepsin L, in concert
with other proteinases such as cathepsin B, matrix metallo-
proteinases (MMPs) and, urokinase type plasminogen acti-
vator (uPA), could facilitate cancer progression (Chauhan et
al., 1991; Wilson and Singh, 2008; Lankelma et al., 2010).
This hypothesis is sustained by a consistent body of exper-
imental and clinical observations which show that the intra-
cellular expression levels of cathepsin L are upregulated in
many human tumors and that this phenomenon is associated
with the onset of more aggressive tumor phenotypes and/or
with a poor clinical outcome (Chauhan et al., 1991; Tum-
minello et al., 1996; Lankelma et al., 2010). It is noteworthy
that altered expression levels of cathepsin L have also been
observed, in particular, in some primary bone tumors such
as osteosarcoma (Park et al., 1996; Haeckel et al., 1999;
Damiens et al., 2000; Kirschke et al., 2000; Krueger et al.,
2001; Husmann et al., 2008), giant cell tumor of the bone
(Park et al., 1996; Lindeman et al., 2004), multiple myeloma
(Spens and Haggstrom, 2005), chondrosarcomas (Park et al.,
1996; So¨derstro¨m et al., 2001), in tumors which preferen-
tially metastasize to the bone such as breast cancer (Harbeck
et al., 2001; Zajc et al., 2002; Caserman et al., 2006), prostate
cancer (Friedrich et al., 1999; Colella et al., 2004; Goo et
al., 2009), lung cancer (Kayser et al., 2003), laryngeal cancer
(Russo et al., 1995), melanoma (Yang and Cox, 2007), oral
cancer (Erdem et al., 2007) and in bone metastases (Park et
al., 1996). These findings are intriguingly regarding a pos-
sible involvement cathepsin L, also in bone metastasis for-
mation. By contrast, several experimental data support this
hypothesis. For instance, Damiens et al. (2000) reported that
human osteosarcoma cell lines MG-63 and SaOS2 produced
cathepsin L. Interestingly, the intracellular levels of this pro-
teinase were increased by proinflammatory cytokines pro-
moting bone resorption such as IL-1b, IL-6 or TNF-a
(Kawamata et al., 1997; Katunuma et al., 2002a; Kwan Tat
et al., 2004; Blanchard et al., 2009). More recently, Husmann
et al. (2008) showed that, in human osteosarcoma cell lines
with different metastatic potential, cathepsin L expression
levels were constitutively upregulated in the highly meta-
static cell line compared with the low metastatic cell line.
This phenomenon was also noted for cathepsins D and K.
Conversely, cathepsins B and H expression levels resulted in
downregulation, whereas cathepsin V was undetectable
either in low or in highly metastatic cell lines (Husmann et
al., 2008). These findings fit well with earlier observations
of Park et al. (1996) who highlighted that cathepsin L was
expressed only in 50% of primary human bone tumors and
in 100% of metastatic tumors. Furthermore, clinical investi-
gations carried out in patients with chondrosarcomas dem-
onstrated that the overexpression of cathepsin L in these
tumors was significantly associated with their progression
(So¨derstro¨m et al., 2001). Although these data are suggestive
of an active involvement of cathepsin L in the pathogenesis
of metastatic bone disease, the possible mechanisms by
which this proteinase could foster this process remain to be
fully unraveled. However, experimental evidence, in this
regard, highlights that the enzyme could facilitate the homing
and the diffusion of metastatic cells into the bone though
multiple mechanisms which are summarized in Table 2.
Thus, in vitro studies suggest that cathepsin L secreted by
malignant cells can directly facilitate the growth and spread
of these cells into the bone by degrading bone matrix pro-
teins (Kawamata et al., 1997; Kirschke et al., 2000; Colella
et al., 2004; Erdem et al., 2007; Gocheva and Joyce, 2007;
Yang and Cox, 2007; Goo et al., 2009; Kielosto et al., 2009;
Ogawa et al., 2009). In addition, the upregulation of osteo-
clast cathepsin L activity induced by proinflammatory cyto-
kines such as PTH and ILs released from tumor cells could
further contribute to degrade bone matrix thus allowing the
homing of metastatic cells into the bone tissue (Katunuma
et al., 2002a; Kwan Tat et al., 2004; Brage et al., 2005;
Everts et al., 2006; Blanchard et al., 2009; Lankelma et al.,
2010) (Table 1). Furthermore, this proteinase can indirectly
promote bone degradation by triggering the activation latent
precursor forms of other proteolytic enzymes, such as MMPs
and uPA, which are known to be involved in the metastatic
cascade and to modulate bone remodeling (Goretzki et al.,
1992; Kawamata et al., 1997; Bjo¨rklund and Koivunen,
2005; Lah et al., 2006; Wilson and Singh, 2008; Lankelma
et al., 2010) (Table 1). Interestingly, recent studies suggested
that cathepsin L could also facilitate the diffusion of meta-
static cells into the bone through specific mechanisms not
related with its bone degrading activity. For instance, it has
been shown that, similarly as described for cathepsin B and
MMPs, cathepsin L can degrade E-cadherin, an adhesion
molecule which is downregulated in metastatic tumor cells,
thus enhancing their migratory and invasive ability (Table 2)
(Gocheva et al., 2006; Lankelma et al., 2010; Martin et al.,
2010; Pontes et al., 2010). These findings could fit well with
previous in vitro observations which showed that the inhi-
bition of cathepsin L mRNA and protein expression by anti-
sense oligonucleotides markedly decreased the motility and
invasive ability of MNNG/HOS osteosarcoma cells (Krueger
et al., 2001). Yet, cathepsin L could contribute to select more
aggressive tumor phenotypes by modulating the intracellular
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Table 2 Possible mechanisms by which cathepsin L could facilitate bone metastasis formation.
Mechanism Effects References
Bone matrix degradation Invasion and metastasis Kawamata et al., 1997; Kirschke et al., 2000;
Colella et al., 2004; Erdem et al., 2007;
Gocheva and Joyce, 2007;
Yang and Cox, 2007; Goo et al., 2009;
Kielosto et al., 2009; Ogawa et al., 2009
Upregulation of osteoclast Bone matrix degradation Katunuma et al., 2002a;
cathepsin L activity induced by Invasion and metastasis Kwan Tat et al., 2004; Brage et al., 2005;
cytokines with bone degrading Everts et al., 2006; Lankelma et al., 2010
activity released by tumor cells
Activation of latent precursor Extracellular matrix degradation Goretzki et al., 1992; Kawamata et al., 1997;
forms of other proteolytic Invasion and metastasis Bjo¨rklund and Koivunen, 2005; Lah et al., 2006;
enzymes involved in the Lankelma et al., 2010
metastatic cascade (MMPs, uPA)
Degradation of E-cadherin Reduced adhesion, increased Krueger et al., 2001; Gocheva et al., 2006;
motility and migration of cancer Lankelma et al., 2010; Pontes et al., 2010
cells
Modulation of IGF-I Onset of aggressive tumor Nakasaki et al., 2008; Navab et al., 2008;
phenotype Lankelma et al., 2010
a) Increased expression of cathepsin Tissue remodeling and tumor Katunuma et al., 2002a,b; Rousselet et al., 2004;
L in endothelial progenitor cells neovascularization Urbich et al., 2005; van Hinsbergh et al., 2006;
Keerthivasan et al., 2007;
b) Interactions with VEGF McMahon and Kwaan, 2008; Chang et al., 2009;
Rebbaa et al., 2009;
c) Activation of pro-MMPs and Deryugina and Quigley, 2010
pro-uPA
d) Stimulation of recruitment and
activity of blood- or bone
marrow-derived cells
expression levels of growth factors and receptors actively
involved in bone remodeling such as insulin growth factor I
(IGF-I) (Damiens et al., 2000; Nakasaki et al., 2008; Navab
et al., 2008; Lankelma et al., 2010). Intriguingly, recent
investigations indicated that cathepsin L can indirectly facil-
itate bone metastasis formation by fostering tumor angioge-
nesis (Table 1). In support of this hypothesis, Urbich et al.
(2005) reported that bone marrow mononuclear cells or cir-
culating blood-derived progenitor cells required cathepsin L
to mediate their invasion activity in vitro and neovasculari-
zation improvement in vivo. Furthermore, cytokines which
promote bone pit resorption such as TNF-a have been shown
to increase the secretion of pro-cathepsin L in bone marrow
cells thus enhancing their invasive activity and facilitating
the formation of new blood vessels (Furuyama and Fujisawa,
2000a,b; Katunuma et al., 2002a,b). Moreover, van Hins-
bergh et al. (2006) recently demonstrated that cathepsin L,
in concert with MMP-9, stimulates the recruitment and
action of blood- or bone-marrow derived accessory cells that
enhance angiogenesis (Table 1). These data are consistent
with those findings which suggested that cathepsin L could
foster tumor angiogenesis by activating latent forms of pro-
teolytic enzymes, such as MMPs and uPA, implicated in this
process (Goretzki et al., 1992; van Hinsbergh et al., 2006;
McMahon and Kwaan, 2008; Wilson and Singh, 2008;
Deryugina and Quigley, 2010). Interestingly, Keerthivasan et
al. (2007) recently showed that, at least in U87MG glioblas-
toma cells, vascular endothelial growth factor (VEGF) can
upregulate at transcriptional level cathepsin L. Consistent
with these observations, Chang et al. (2009) highlighted that
in human breast cancer cells, VEGF-A can promote angio-
genesis by perturbing the cathepsin-cysteine protease inhib-
itor balance in venules causing basement membrane
degradation. A direct proof of the importance of cathepsin
L-VEGF interactions in promoting tumor angiogenesis in
different tumors is provided, in part, by some in vitro studies
which showed that the inhibition of human procathepsin L
secretion by anti-cathepsin L monoclonal antibody resulted
in an inhibition of tumor-induced angiogenesis in highly met-
astatic human melanoma cells (Rousselet et al., 2004; Frade
et al., 2008). Furthermore, Rebbaa et al. (2009) recently dem-
onstrated that Napsul-IIe-Trp-CHO, a specific inhibitor of
cathepsin L, inhibited in vitro VEGF secretion by endothelial
cell and cathepsin L-mediated degradation of the extracel-
lular matrix. Whereas, in vivo, this molecule was able to in-
hibit tumor growth in nude mice transplanted neuroblastoma.
Cathepsin L inhibitors in the treatment of
cancer related bone disease
Experimental findings suggestive of an active role of cathep-
sin L in the pathogenesis of metastatic bone disease have
led, in recent years, to the development of a series of inhib-
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itors of this proteinase. These molecules, administered in
association with antagonists of other proteinases promoting
bone metastasis such as cathepsin K and MMPs (Wilson and
Singh, 2008), could contribute to elicit a better therapeutic
response in the treatment of this pathological condition. Fur-
thermore, these drug combinations might, eventually, over-
come the pitfall of the functional redundancy of cathepsin K
and cathepsin L in bone (Nagler and Menard, 2003; Fal-
gueyret et al., 2005; Brix et al., 2008). Another rationale for
the development of new specific cathepsin L antagonist relies
on the observations that the proteolysis required for tumor
invasion occurs mostly extracellularly (Mohamed and
Sloane, 2006; Lankelma et al., 2010). This phenomenon
could, in part, explain why, during tumor progression, intra-
cellular cathepsin L translocates from lysosomes to the cell
membranes and then is actively secreted into the acid extra-
cellular microenvironment of tumors (Chauhan et al., 1998;
Katunuma et al., 2002a; Ravanko et al., 2004; Hashimoto et
al., 2006; Mohamed and Sloane, 2006; Goo et al., 2009;
Ogawa et al., 2009). Therefore, the alternative strategies that
can target secreted proteinases such as cathepsin L are actu-
ally appealing as the use of molecules which act extracel-
lularly and do not enter cells can overcome potential toxic
effects owing to the inhibition of other proteinases present
in the lysosomal compartment of normal cells (Hill et al.,
1994; Falgueyret et al., 2005; Black and Percival, 2006; Le
Gall et al., 2008; Lankelma et al., 2010). This latter phenom-
enon is, currently, of main concern regarding for instance,
the long-term use of some specific inhibitors of cathepsin K
in the treatment of bone disease. In fact, these agents, owing
to their lysosomotropic nature, by accumulating inside lyso-
somes, can block the normal activity of other proteinases
thus inducing potential adverse effects (Falgueyret et al.,
2005; Black and Percival, 2006; Desmarais et al., 2008; Le
Gall et al., 2008). In this context, current efforts are specif-
ically directed to design new suitable cathepsin K inhibitors
which could be devoid of these potential side effects (Black
and Percival, 2006; Desmarais et al., 2008; Le Gall et al.,
2008; Bro¨mme and Lecaille, 2009). Most of the cathepsin L
targeted agents which have been developed are a series of
different classes of antagonists including small molecule
inhibitors with a higher selectivity for cathepsin L (Katu-
numa et al., 2002a,b; Marquis et al., 2005; Sadaghiani et al.,
2007; Myers et al., 2008; Palermo and Joyce, 2008; Yadav
et al., 2008; Asaad et al., 2009; Bethel et al., 2009; Long
and Chagnovich, 2009; Rebbaa et al., 2009; Kishore Kumar
et al., 2010), alternative forms of endogenous inhibitors
(Brand et al., 2004; Gianotti et al., 2008), antibodies and
antisense oligonucleotides (Krueger et al., 2001; Rousselet
et al., 2004; Frade et al., 2008; Long and Chagnovich, 2009)
or natural products (Lion et al., 2009; Ogawa et al., 2009).
Preclinical studies showed that some of these molecules were
effective to inhibit, in vitro, bone matrix digestion at the level
of resorption lacuna and to promote bone mineralization,
whereas, in vivo, these agents were able to suppress RANKL
or M-CSF or TNF-a stimulated bone pit formation and to
protect tumor bearing mice from malignant hypercalcemia
and to decrease bone metastasis formation (Hill et al., 1994;
Katunuma et al., 2002a,b; Brand et al., 2004; Long and Cha-
gnovich, 2009). Interestingly, recent investigations have pro-
posed, as a novel approach, to inhibit proteinase-mediated
bone resorption, the use of molecules, such as oligogalac-
turonic acid (OGA) purified from flax pectin which specif-
ically target the collagenase function of proteases involved
in cancer progression, including cathepsin L, without affect-
ing their proteolytic activity (Lion et al., 2009). These
authors speculated that, owing to the physiological role of
human cathepsins and MMPs in bone collagen degradation
(Maciewicz et al., 1990; Li et al., 2004; Everts et al., 2006;
Charni-Ben Tabassi et al., 2008), OGA, according to its spe-
cific mechanism of action, could be of therapeutic benefit in
the treatment of disorders associated with an increased bone
resorption such as osteolytic bone metastasis (Lion et al.,
2009). In addition, owing to its peculiar mechanism, this
compound could have therapeutic advantages over classical
active site inhibitors regarding their potential side effects.
Although the preclinical studies on the effectiveness of
cathepsin L inhibitors in preventing bone metastasis forma-
tion are promising, there are some valid concerns regarding
the clinical use of these molecules. Some of these concerns
rely on recent observations that cathepsin L could also act
as pro-apoptotic and tumor suppressive molecules (Lah et
al., 2006; Di Piazza et al., 2007; Vasiljeva and Turk, 2008;
Hsu et al., 2009; Dennema¨rker et al., 2010; Lankelma et al.,
2010). These findings indicate that, in this case, the use of
cathepsin L antagonists could be detrimental. However,
experimental evidence highlights that, at least in most human
tumors, cathepsin L appears to act mainly as tumor promot-
ing proteinase (Zheng et al., 2004, 2008, 2009; Rebbaa et
al., 2009), whereas the tumor suppressor activity of this
endopeptidase appeared to be restricted only to some squa-
mous cell carcinomas and gliomas (Lah et al., 2006; Di Piaz-
za et al., 2007; Hsu et al., 2009; Dennema¨rker et al., 2010;
Lankelma et al., 2010). Experimental studies indicate that
the pro-apoptotic effects of cathepsin L in these tumors could
probably be related to specific functions carried out by this
enzyme in the tissue homeostasis of normal counterparts
(Lah et al., 2006; Sevenich et al., 2006; Di Piazza et al.,
2007; Vasiljeva and Turk, 2008; Hsu et al., 2009; Denne-
ma¨rker et al., 2010; Lankelma et al., 2010). By contrast, no
pro-apoptotic or growth inhibiting activity of cathepsin L on
primary bone tumor cells and in bone metastatic cells has
been reported so far.
Conclusion and perspectives
Growing evidence highlights that cathepsin L, in concert
with other proteinases such as cathepsin K, MMPs and uPA,
could contribute to promote bone metastasis formation
(Katunuma et al., 2002a,b; Navab et al., 2008; Palermo and
Joyce, 2008; Wilson and Singh, 2008; Lankelma et al.,
2010). These findings imply that the use of a single molecule
directed to inhibit a specific target enzyme might not be
effective in preventing and/or eradicating bone metastasis.
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Therefore, more effective treatments of this pathological con-
dition should rely on the combination of molecules which
can act on different classes of proteolytic enzymes which
contribute equally to facilitate the homing and spread of met-
astatic cells into the bone (Yamamoto et al., 2002; Krol et
al., 2003; Palermo and Joyce, 2008; Lion et al., 2009; Long
and Chagnovich, 2009; Lankelma et al., 2010). In this sce-
nario, cathepsin L inhibitors could be regarded as additional,
potential therapeutic tools in the clinical management of
patients with bone metastasis. Furthermore, recent studies
which show that cathepsin L appears to act as a pro-survival
factor and could contribute to the development of antitumor
drug resistance (Zheng et al., 2004; Gocheva et al., 2006;
Zajc et al., 2006; Navab et al., 2008; Zheng et al., 2008,
2009; Lankelma et al., 2010) further stress the potential clin-
ical benefit of cathepsin L inhibitors in reverting antitumor
drug resistance (Zheng et al., 2004, 2009; Palermo and
Joyce, 2008; Rebbaa et al., 2009; Lankelma et al., 2010).
Therefore, the combination of cathepsin L antagonists with
classical anticancer drugs appears to be a promising thera-
peutic option also in the treatment of cancer-related bone
diseases resistant to conventional antitumor agents (Palermo
and Joyce, 2008; Zheng et al., 2008, 2009; Lankelma et al.,
2010). Although preclinical studies on the effectiveness of
cathepsin L inhibitors in preventing bone metastasis are
encouraging, it remains to be established whether these
results could be translated to the clinic. Further investigations
are needed to better define the pharmacological and toxico-
logical profile of these molecules in humans and their effect-
iveness in the treatment of metastatic bone disease. These
studies could unravel the clinical value of these molecules
in the therapeutic management of patients with primary bone
cancer and/or skeletal metastasis.
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